Compare Amgen, Inc. (AMGN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: Amgen, Inc. is far larger — about 123.8× Recursion Pharmaceuticals Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMGN | RXRX | |
|---|---|---|
Market Cap | $224.14B | $1.81B |
Sector | Health | Health |
52-Week High | $417.20 | $6.79 |
52-Week Low | $271.18 | $2.84 |
Enterprise Value | $267.45B | $1.33B |
Dividend Yield | 2.43% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
